Global Information
회사소개 | 문의 | 비교리스트

헌터증후군 치료 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 995767
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
US $ 4,750 ₩ 6,364,000 PDF & Excel (Single User License)
US $ 5,250 ₩ 7,033,000 PDF & Excel (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,708,000 PDF & Excel (Site License)
US $ 8,750 ₩ 11,723,000 PDF & Excel (Corporate License)

헌터증후군 치료 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 헌터증후군 치료 시장 규모는 2020년에 9억 4,200만 달러를 기록했습니다.

시장은 예측기간(2021-2026년)에 약 5.2%의 CAGR로 확대되고, 2026년까지 12억 6,500만 달러에 달할 것으로 예측됩니다.

COVID-19 팬데믹은 공공의 이동성 저하를 가져오고, 진단 업계에도 영향을 미쳤습니다. 신종 코로나바이러스 감염을 회피하기 위해서 긴급하지 않은 일부 진단이나 치료가 보류되었습니다.

National MPS Society에 의하면 헌터증후군은 주로 남성 10만명에 1명에서 17만명에 1명으로 발병하는 희귀질환입니다. 환자에게는 iduronate sulfatase 효소가 존재하지 않습니다. 이것은 뮤코다당 데르마탄 황산과 헤파란 황산을 분해하기 위해서 필수적입니다. 이러한 물질은 신체의 세포에 저장되어 진행성 손상을 일으킵니다.

시장 성장은 정부 정책 증가, 새로운 치료법 도입 및 강력한 파이프라인에 기인하고 있습니다. 또한 헌터증후군과 치료 옵션의 이용 가능성에 대한 인식 확산은 시장 매출 성장을 추진합니다.

2018년 Shire plc는 International MPS Network 및 National MPS Society와 함께 MPS(뮤코다당) 질환과 미국에서 25,000명에 1명의 출생에 영향을 미치는 이 질환에 대한 인식을 높이기 위해 #FlyforMPS 캠페인을 개시했습니다. 또한 2018년에 국립보건원에 의해 발표된 보고에 의하면 세계적으로 헌터증후군 질병은 남성 16만명에 1명이 이환하고 있고, 희귀질환이 되고 있습니다. 따라서 연구개발비 증가, 새로운 치료법 승인, 시장 참가자에 의한 몇 가지 이니셔티브 및 이 희귀질환 치료를 위한 신기술 채용에 관한 기술 진보가 시장 전체의 성장을 지지할 것으로 보입니다.

세계의 헌터증후군 치료(Hunter Syndrome Treatment) 시장에 대해 조사했으며, 시장 개요와 함께 치료 종류별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.


제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 추진력
    • 정부 정책 증가
    • 신규 치료법 도입
    • 견고한 파이프라인
  • 시장 성장 억제요인
    • 높은 치료비
  • Porter's Five Force 분석

제5장 시장 세분화

  • 치료 종류별
    • 효소보충요법(ERT)
    • 조혈모세포 이식(HSCT)
    • 기타
  • 최종사용자별
    • 병원
    • 진단 센터
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제6장 경쟁 상황

  • 기업 개요
    • REGENXBIO Inc.
    • Takeda Pharmaceutical Company Limited(Shire)
    • Clinigen Group plc
    • JCR Pharmaceuticals
    • ArmaGen
    • Sangamo Therapeutics
    • Denali Therapeutics Inc.
    • Bioasis Technologies Inc.
    • Inventiva
    • GC Pharma(Green Cross Holdings)
    • Esteve
    • Avrobio, Inc.
    • CANbridge Life Sciences Ltd.

제7장 시장 기회와 동향

KSM 21.03.22

The Hunter syndrome treatment market was valued at an estimated market size of USD 942 million in 2020, and it is expected to reach USD 1,265 million by 2026, registering a CAGR of nearly 5.2% during the forecast period, 2021-2026.

The COVID-19 pandemic has resulted in decreased public mobility, as well as impacted the diagnostic industries. Several diagnostic procedures and therapy that are non-emergent were put on hold to avoid the transmission of the novel coronavirus.

As per the National MPS Society, Hunter syndrome is a rare condition that affects 1 in 100,000 to 1 in 170,000, primarily males. It is the absence of enzyme iduronate sulfatase in patients, which is essential to break down the mucopolysaccharides dermatan and heparan sulphate. These materials are stored in the body's cells, causing progressive damage.

The market growth is attributed to increasing government initiatives, the introduction of novel therapies, and robust pipelines. In addition, growing awareness about Hunter syndrome and the availability of therapeutic options may propel the revenue growth of the market.

In 2018, Shire PLC, with International MPS Network and National MPS Society, launched the #FlyforMPS campaign to raise awareness about MPS (mucopolysaccharide) diseases, and this disease is affecting at least one in 25000 births in the United States. Moreover, a report was published by the National Institute of Health in 2018 that states that globally, Hunter syndrome disease is affecting 1 in 160,000 males, making it a rare disease. Thus, increasing R&D expenditure, approval of novel therapies, several initiatives by market players, and technological advancements in terms of adopting new technologies for the treatment of this type of rare disease are likely to fuel the growth of the overall market.

Key Market Trends

The Enzyme Replacement Therapy (ERT) Segment is Estimated to Witness Healthy Growth in the Future

The enzyme replacement therapy segment is estimated to witness notable growth in the future attributed to increasing awareness, rising availability of enzyme replacement therapy, and less stringent guidelines.

Enzyme replacement therapy (ERT) is a standard of care for several types of rare diseases. ERT consists of replacing the deficient or absent enzyme with a functional recombinant version through intravenous administration. In addition, several products in ERT sales have been significantly increased, which results in the segment growth. For example, Idursulfase manufactured by Shire PLC is used for the treatment of Hunter disease. In addition, idursulfase beta by Clinigen Group PLC will fulfill the unmet need for this type of disease.

Furthermore, in 2017, Shire PLC announced top-line results from its Phase II/III clinical trial evaluating SHP609, previously known as HGT-2310. It is an investigational formulation of idursulfase administered intrathecally for a new potential indication for the treatment of pediatric patients with Hunter syndrome (mucopolysaccharidosis II or MPS II) and cognitive impairment.

As per a 2020 European study, titled 'Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment', the incidence rate of Hunter syndrome ranges from 0.38 per 100,000 live newborns in Brazil to 1.09 per 100,000 live newborns in Portugal and European countries, generally present a lower incidence than East Asian countries, whereas MPS II incidence accounts for about 50% of all mucopolysaccharidoses.

Thus, the growing adoption of these therapies by the target patient pool and growing product approvals may trigger the growth of enzyme replacement therapy.

North America is Expected to Hold a Significant Share in the Forecast Period

North America holds a significant market share due to rising awareness regarding rare diseases, favorable regulations for orphan drug development, growing healthcare expenditure, and favorable reimbursement policies. In 2018, US healthcare accounted for 17.9% of the GDP. The United States is one of the major destinations for all the recent advancements in the field of medicine.

Furthermore, well-established healthcare infrastructure, increasing adoption of novel therapies, and technological advancements are also expected to fuel the Hunter syndrome market in this region. For instance, in December 2019, REGENXBIO Inc., a US-based company, announced interim data from the first cohort of the ongoing Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (Hunter syndrome). It is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase enzyme direct to the central nervous system (CNS) using the AAV9 vector.

Competitive Landscape

The Hunter syndrome market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are REGENXBIO Inc., Takeda Pharmaceutical Company Limited, Clinigen Group PLC, JCR Pharmaceuticals, ArmaGen, Sangamo Therapeutics, Denali Therapeutics Inc., Bioasis Technologies Inc., Inventiva, etc. Additionally, the key players have been involved in various strategic alliances, along with the launch of advanced products, to secure their positions in the global market. For instance, in October 2020, AVROBIO Inc. announced an exclusive, worldwide license agreement and a collaborative research funding agreement with The University of Manchester for investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome, a rare and deadly lysosomal disorder that primarily affects young boys.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government Initiatives
    • 4.2.2 Introduction of Novel Therapies
    • 4.2.3 Robust Pipelines
  • 4.3 Market Restraints
    • 4.3.1 High Treatment Costs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Treatment Type
    • 5.1.1 Enzyme Replacement Therapy (ERT)
    • 5.1.2 Hematopoietic Stem Cell Transplant (HSCT)
    • 5.1.3 Other Treatment Types
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Rest of the World


  • 6.1 Company Profiles
    • 6.1.1 REGENXBIO Inc.
    • 6.1.2 Takeda Pharmaceutical Company Limited (Shire)
    • 6.1.3 Clinigen Group PLC
    • 6.1.4 JCR Pharmaceuticals
    • 6.1.5 ArmaGen
    • 6.1.6 Sangamo Therapeutics
    • 6.1.7 Denali Therapeutics Inc.
    • 6.1.8 Bioasis Technologies Inc.
    • 6.1.9 Inventiva
    • 6.1.10 GC Pharma (Green Cross Holdings)
    • 6.1.11 Esteve
    • 6.1.12 Avrobio Inc.
    • 6.1.13 CANbridge Life Sciences Ltd


Back to Top
전화 문의